Press Releases Alterity Therapeutics Limited

Equities

ATH

AU0000043945

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		0.00%	-14.29%

Apr. 16	ADRs End Lower, Purple Biotech Ltd. Declines 29%	DJ
Apr. 12	ADRs End Lower, Leju Holdings Ltd. Declines 72%	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	Mar. 26	AQ
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	Mar. 25	PU
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	Mar. 15	PU
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	AQ
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week	Jan. 29	AQ
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones	Jan. 22	AQ
Alterity Therapeutics : Presentation to Extraordinary General Meeting	Dec. 28	PU
Alterity Therapeutics : Target Market Determination (TMD) for the placement options offered under the Company’s prospectus dated 29 December 2023	Dec. 28	PU
Alterity Therapeutics : Target Market Determination (TMD) for the free attaching SPP options offered under the Company’s prospectus dated 29 December 2023	Dec. 28	PU
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer	Dec. 21	AQ
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress	Dec. 04	AQ
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease	Dec. 04	AQ
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	Nov. 30	PU
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy	Nov. 27	AQ
Alterity Therapeutics : Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434	Nov. 15	PU
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy	Nov. 08	AQ
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	23-10-31	PU
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report	23-10-30	AQ
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder	23-08-31	AQ
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s	23-08-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alterity Therapeutics Limited

Equities

ATH

AU0000043945

Press Releases

Filters